NCT05209620View on ClinicalTrials.gov

Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 21, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

December 21, 2026

Conditions
Central Nervous System Lymphoma
Interventions
DRUG

ICP-022

"Induction Chemotherapy: Orelabrutinib, 150mg/d continuous oral administration (3 weeks/cycle, total 6 cycles).~Maintenance Treatment: Orelabrutinib, 150mg/d continuous oral administration (28d/cycle)."

DRUG

Pemetrexed

Induction Chemotherapy: Pemetrexed, 500mg/m2, Intravenous administration on day 5 of each 3-week cycle (Total 6 cycles).

Trial Locations (1)

Unknown

RECRUITING

Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV